Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-05-24 00:00:00 ET · period of report 2023-05-23 · accession 0001799191-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-24 | 2023-05-23 | STLN | Shah Mihir | CFO | D - Sale to Iss | $0.43 | -3,442 | 224.3K | -2% | -$1,480 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-23 | D | D | 869 | $0.43 | 223,472 | D | — | — | (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on May 23, 2023 within a one-dollar range. Actual prices ranged from $0.4201 to $0.4600. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2023-05-23 | D | D | 2,573 | $0.43 | 224,341 | D | — | — | (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on May 23, 2023 within a one-dollar range. Actual prices ranged from $0.4201 to $0.4600. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |